From Chicago: elotuzumab is a monoclonal antibody, is basically only in the Mbl1 myeloma cells. The researchers say: even if these patients with other medical therapy, the disease continued development; elotuzumab treatment, these patients more than 90% of the treatment of the objective.By Philippe of Moreau's message: a Phase II clinical trials, after a follow-up of 17.2 months, using the 10 mg dose of elotuzumab therapy patients still do not get the MBL2 median progression-free survival. MD Philippe of Moreau, France at Nance City University Department of Hematology, Hotel-Dieu Hospital Director."In phase III clinical studies are still using the 10 mg dose of Moreau in the oral speech of the American Society of Clinical Oncology annual meeting of this introduction. This Phase II clinical study tested the 20 mg dose; found that the dose group is greater than the side MBP effects of the 10 mg dose group, a lower efficacy. In a conference on the treatment of multiple myeloma therapy, he reported that: the trial of high dose group median progression-free survival was 18.6 months.Patients recruited in this study used at least in the previous first-line drug therapy, the disease progress in at least 1; during elotuzumab, lenalidomide (lenalidomide,) and dexamethasone (of dexamethasone) before MCAM treatment, only been a first-line treatment of patients, 91% of patients achieved the target response.In addition to the observed therapeutic effect (effectiveness), Phase II clinical research study carefully the safety of the drug. Two-dose group, has more than half of the patients had diarrhea, muscle cramps and constipation, but only less than 10% of patients had 3 to 4 times side effects. Patients taking 10 mg dose is approximately 1/3 of the MCEE back pain, 22% in the high dose group throughout the study, only 2 patients with 3 to 4 back pain.
Rafael Fonseca, said: "Bone is a big problem for patients with bone tumors." The M.D. Rafael Fonseca, the medical director of the Mayo Clinic in Scottsdale, Arizona, USA. He said: "at least 70% of patients with myeloma bone disease; we really do not have good biological markers for diagnosis. The event of a fracture, a bit like archeology, we are checking the ruins."Moreau prompt: In the phase I clinical dose range test, 82% of the 28 patients reached the target reaction. In that study, the dose is not yet high reach dose-limiting toxicity; did not reach the median progression-free survival; did not reach the maximum tolerated dose. Phase II clinical study was designed to exceed these numbers - 10 mg dose has been completed this initiative, 92% of patients had a target reaction.The Phase II clinical study recruited 73 patients. 30 days for a course, 1,8,15,22 days in each course of treatment, these patients received 10 mg / kg or 20 mg / kg elotuzumab treatment. All treated patients, plus a daily serving of 25 mg of lenalidomide (lenalidomide,), plus a week to service of 40 mg dexamethasone (dexamethasone). Until the course of the patient's progress or produce unacceptable toxicity, stop the treatment process. Dexamethasone the elotuzumab treatment before administration. Qualified patient refers to patients with recurrent or multiple myeloma, measurable M protein, kidney function can accept.Moreau and colleagues recruited 36 patients recruited in the 10 mg group, 37 patients recruited in the 20 mg group. The median age of these patients was 63 years elapsed from diagnosis to recruit about 4.5 years; 55% of the treatment after 2 or more times; 82% had stem cell transplants; 62% before Sally polyamine treatment.Moreau said that half of patients stop treatment - 12 because of disease progression, two because of side effects; in the 20 mg group, 65% of patients stopped treatment: 10 mg group - 12 because of disease progression, is because of side effects.